Briakinumab is an investigational anti-IL-12/23 monoclonal antibody for the treatment of psoriasis.
In a filing with the Securities and Exchange Commission, the company said following feedback from regulatory authorities indicating the need for further analysis and the potential for additional studies, Abbott plans to evaluate next steps for briakinumab, including resubmission at a later date.